Rapamycin-13C,d3

• UNSPSC Description:

  Rapamycin-13C,d3 (Sirolimus-13C,d3; AY-22989-13C,d3) is the 13C and deuterium labeled Rapamycin (HY-10219)[1]. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[2]. Rapamycin is an autophagy activator, an immunosuppressant[3].

• Target Antigen:

  Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Others

• Field of Research:

  Others

• Purity:

  97.05

• Solubility:

  10 mM in DMSO|DMSO : 125 mg/mL (ultrasonic;warming)

• Smiles:

  O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)O[13C]([2H])([2H])[2H])O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O

• Molecular Weight:

  918.18

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, protect from light, stored under nitrogen)

• Clinical Information:

  No Development Reported